-
Mashup Score: 0Meeting Library | Meeting Library - 2 year(s) ago
2318 Mill Road, Suite 800, Alexandria, VA 22314 · 571-483-1300 © American Society of Clinical Oncology (ASCO). All Rights Reserved Worldwide.
Source: meetinglibrary.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Meeting Library | Meeting Library - 2 year(s) ago
2318 Mill Road, Suite 800, Alexandria, VA 22314 · 571-483-1300 © American Society of Clinical Oncology (ASCO). All Rights Reserved Worldwide.
Source: meetinglibrary.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
.@HealthTreePatient Portal mediated myeloma patient-reported vaccination and antibiotic use - @mtmdphd @AhlstromJenny Sweeney J Clin Oncol 38: 2020 (suppl;abstr e20567) #ASCO20 https://t.co/MwCOajVidj #mmsm #IDonc https://t.co/ZWPkUXcxPT
-
-
Mashup Score: 0Meeting Library | Meeting Library - 2 year(s) ago
2318 Mill Road, Suite 800, Alexandria, VA 22314 · 571-483-1300 © American Society of Clinical Oncology (ASCO). All Rights Reserved Worldwide.
Source: meetinglibrary.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
HealthTree Patient Portal mediated myeloma patient reported diagnostic imaging and pathology testing - Sweeney @AhlstromJenny @mtmdphd J Clin Oncol 38: 2020 (suppl; abstr e20565) #ASCO20 https://t.co/CRLXETpeMm #mmsm #oncorad #oncopath @myelomacrowd https://t.co/s9uTYyZNuR
-
-
Mashup Score: 0Meeting Library | Meeting Library - 2 year(s) ago
2318 Mill Road, Suite 800, Alexandria, VA 22314 · 571-483-1300 © American Society of Clinical Oncology (ASCO). All Rights Reserved Worldwide.
Source: meetinglibrary.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
.@HealthTreePatient Portal mediated myeloma patient-reported vaccination and antibiotic use - @mtmdphd @AhlstromJenny Sweeney J Clin Oncol 38: 2020 (suppl;abstr e20567) #ASCO20 https://t.co/ubmfK482XK #IDonc
-
-
Mashup Score: 1Meeting Library | Meeting Library - 2 year(s) ago
2318 Mill Road, Suite 800, Alexandria, VA 22314 · 571-483-1300 © American Society of Clinical Oncology (ASCO). All Rights Reserved Worldwide.
Source: meetinglibrary.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
HealthTree Patient Portal mediated myeloma patient reported diagnostic imaging and pathology testing - Sweeney @AhlstromJenny @mtmdphd J Clin Oncol 38: 2020 (suppl; abstr e20565) #ASCO20 https://t.co/CRLXETpeMm #mmsm #oncorad #oncopath @myelomacrowd https://t.co/OstRPinphh
-
-
Mashup Score: 3
The use of social media continues to increase in health care and academia. Health care practice, particularly the oncologic field, is constantly changing because of new knowledge, evidence-based research, clinical trials, and government policies. Therefore, oncology trainees and professionals continue to strive to stay up-to-date with practice guidelines, research, and skills. Although social…
Source: JCO Oncology PracticeCategories: Hem/Oncs, Latest HeadlinesTweet-
#SoMe & Professional Development for Oncology Professionals https://t.co/B0pc4uazp6 @JCOOP_ASCO #COSMO Best advice: Speak plainly & clearly. It will help you in everything you do! (Table 3) Photos: #ASCO19 Tweetup, #ASCO20 #MHC20 @doctormb1 @RManochakian @GvanLondenMD https://t.co/yGxLRqDx2t
-
-
Mashup Score: 8Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108) - 2 year(s) ago
PURPOSE Distant metastases are present in 6% or more of patients with newly diagnosed breast cancer. In this context, locoregional therapy for the intact primary tumor has been hypothesized to improve overall survival (OS), but clinical trials have reported conflicting results. METHODS Women presenting with metastatic breast cancer and an intact primary tumor received systemic therapy for 4-8…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Presented at #ASCO20 plenary, out in @JCO_ASCO results of @eaonc trial showing no benefit for local therapy for primary tumor in de novo stage IV #BreastCancer: pity it was conducted before availability of current effective systemic therapies @OncoAlert https://t.co/gn3SHX7WX7
-
-
Mashup Score: 1Meeting Library | Meeting Library - 2 year(s) ago
2318 Mill Road, Suite 800, Alexandria, VA 22314 · 571-483-1300 © American Society of Clinical Oncology (ASCO). All Rights Reserved Worldwide.
Source: meetinglibrary.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Molecular alterations w/ hyperprogression in lung cancer Pts Tx'd w/ immune checkpoint inhibitors in a large health system - Tadesse et al. Abst e15082 #ASCO20 https://t.co/b8M7tBHYGO #ImmunoOnc #lcsm Only STK11/LKB1 mut assoc w/ HP (P =< 0.0001) w/ 5/6 STK11 ICI Tx'd showing HP https://t.co/jduSsltSyo
-
-
Mashup Score: 0Effect of ARID1a oncogenic loss of function mutations on overall survival in metastatic breast cancer patients. - 2 year(s) ago
e13068 Background: ARID1a (AT Rich Interactive Domain 1A) is part of the SWI/SNF complex, which regulates gene transcription. Its inactivation has been shown to determine resistance to endocrine therapy via enrichment of basal-like gene expression features [Xu G., 2020]. We recently reported that ARID1a lower gene expression might be associated with worse overall survival (OS) [Mariotti V.,…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Effect of ARID1a oncogenic loss of function mutations on overall survival in metastatic breast cancer patients [May 25, 2020] @VeroEmme3004 & Soliman Abstract e13068 #ASCO20 https://t.co/FYT2y26VGA #bcsm #PrecisionMedicine @cbioportal @OncoKB
-
-
Mashup Score: 66
Novartis announced today that the US Food and Drug Administration (FDA) has accepted and granted Priority Review to the company’s New Drug Application (NDA) for 177Lu-PSMA-617, an investigational targeted radioligand therapy for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in the post androgen receptor pathway inhibition, post taxane-based
Source: NovartisCategories: Latest Headlines, UrologyTweet-
JUST IN: @US_FDA grants Priority Review for investigational radioligand 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer! @OncoAlert @PCF_Science @PCFnews @soulehoward1 @charlesryanmd Trial presented #ASCO20 @ASCO, published in @NEJM https://t.co/Zk4yBoR6E4 https://t.co/YcmYjdXXAQ
-
HealthTree Patient Portal mediated myeloma patient reported diagnostic imaging and pathology testing - Sweeney @AhlstromJenny @mtmdphd J Clin Oncol 38: 2020 (suppl; abstr e20565) #ASCO20 https://t.co/CRLXETpeMm #mmsm #oncorad #oncopath @myelomacrowd https://t.co/J3H0jzK9AW